BlackRock Amends Catalyst Pharma Stake (SC 13G/A)
Ticker: CPRX · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, pharmaceuticals
TL;DR
**BlackRock updated its passive stake in Catalyst Pharma; watch for market reaction.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 22, 2024, indicating a change in their ownership of Catalyst Pharmaceuticals Inc. common stock as of December 31, 2023. This filing, Amendment No. 7, shows BlackRock's updated passive investment stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in a company's future prospects, potentially influencing other investors.
Why It Matters
This filing updates BlackRock's passive ownership in Catalyst Pharmaceuticals, providing transparency on a major institutional investor's position, which can influence market sentiment.
Risk Assessment
Risk Level: low — This is a routine update from a passive investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued passive interest in Catalyst Pharmaceuticals, but this filing alone doesn't suggest a need for immediate action. It's a routine update, not a change in investment strategy.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- CATALYST PHARMACEUTICALS, INC. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 7 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7)' sections.
Who is the reporting person in this filing?
The reporting person, or the entity that filed this document, is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What is the subject company whose securities are being reported?
The subject company is CATALYST PHARMACEUTICALS, INC., as specified under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC.' and 'CATALYST PHARMACEUTICALS INC (Name of Issuer)'.
What was the date of the event that triggered this filing?
The date of the event which requires the filing of this statement was December 31, 2023, as stated under '(Date of Event Which Requires Filing of this Statement)'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding CATALYST PHARMACEUTICALS, INC. (CPRX).